Drug intelligence / Profile preview

Oradoxel

Development stage: Phase 1
Lead developer: Athenex
Modality: Small Molecules
Administration: Oral

Overview

**Oradoxel** is an investigational oral oncology regimen consisting of **docetaxel** administered with **encequidar** (HM30181A), an intestine-restricted P-glycoprotein inhibitor intended to improve oral docetaxel absorption. Docetaxel is a taxane antineoplastic that binds beta-tubulin and stabilizes microtubules, disrupting mitosis and promoting cancer-cell death. Oradoxel was developed by Athenex and collaborators as an oral alternative to intravenous docetaxel and was evaluated in Phase 1 studies in advanced malignancies and metastatic prostate cancer.

Brand names: Oradoxel
Other names: oral docetaxel + encequidaroral docetaxel + HM30181A

Targets

ABCB1 (P-glycoprotein)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on Oradoxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oradoxel.

Explore the full profile